Table 1.
Baseline characteristics
| Characteristic | All patients (n = 49) |
|---|---|
| Median age at COVID-19 diagnosis, years (range) | 56 (30–85) |
| Female sex, n (%) | 25 (51.0) |
| Race, n (%) | |
| White | 17 (34.7) |
| Other | 17 (34.7) |
| African American | 10 (20.4) |
| Unknown | 5 (10.2) |
| Ethnicity, n (%) | |
| Non-Hispanic | 27 (55.1) |
| Hispanic | 17 (34.7) |
| Unknown | 5 (10.2) |
| Baseline comorbidities, n (%) | |
| Diabetes | 15 (30.6) |
| Hypertension | 19 (38.8) |
| Obesity (BMI ≥ 35) | 10 (20.4) |
| Hyperlipidemia | 26 (53.1) |
| History of ASCVD | 8 (16.3) |
| Rituximab indication, n (%) | |
| Non-Hodgkin’s lymphoma | 18 (36.7) |
| Hodgkin’s lymphoma | 1 (2.0) |
| CD20 + B-cell ALL | 2 (4.1) |
| Autoimmune hematologic disorders (ITP, AIHA, pure red cell aplasia) | 5 (10.2) |
| Rheumatoid Arthritis | 5 (10.2) |
| Autoimmune neurologic diseases (myasthenia gravis, autoimmune encephalitis, CIDP, MS, NMOSD) | 5 (10.2) |
| Vasculitis | 4 (8.2) |
| Inflammatory myopathy | 3 (6.1) |
| Bullous skin disorders | 2 (4.1) |
| Antibody-mediated solid organ transplant rejection | 2 (4.1) |
| Lupus | 1 (2.0) |
| Sarcoidosis | 1 (2.0) |
| Median number of rituximab doses since 2/2019 (range) | 4 (1–10) |
| COVID-19-directed treatments, n (%) | |
| Hydroxychloroquine | 28 (57.1) |
| Azithromycin | 26 (53.1) |
| Steroids | 15 (30.6) |
| Remdesivir | 10 (20.4) |
| Tocilizumab | 1 (2.0) |
| Convalescent plasma | 6 (12.2) |
BMI body mass index, ASCVD atherosclerotic cardiovascular disease, B-ALL B-cell acute lymphoblastic leukemia/lymphoma, ITP immune thrombocytopenic purpura, AIHA autoimmune hemolytic anemia, CIDP chronic inflammatory demyelinating polyneuropathy, MS multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder